Literature DB >> 8519358

Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine.

G Giammanco1, S Li Volti, I Salemi, G Giammanco Bilancia, L Mauro.   

Abstract

A combined vaccine against measles (Edmonston-Zagreb 19 strain), mumps (Rubini strain) and rubella (Wistar RA 27/3 strain) was administered to a group of 46 children aged 10-12 months simultaneously with booster doses of compulsory diphtheria-tetanus toxoid and oral poliovirus vaccine. A second group of 53 children aged 15-24 months who had received booster doses of the compulsory vaccines 5 to 12 months before was also vaccinated. The same seroconversion rates (100%) and similar antibody titers for rubella were observed in both groups. The same seroconversion rates for mumps (93%) and similar rates for measles (98 and 94%) were observed in the two groups. Significantly lower antibody titers for measles and mumps were found in the first group, but they were compensated by an earlier protection, a reduction of number of visits for immunization, costs for the community, and improvement in parental compliance. These results confirm that Edmonston-Zagreb 19 and Rubini strains are still immunogenic even when they are combined with Wistar RA 27/3 strain. Moreover, a long term follow-up in order to verify the persistence of protective antibody levels in both groups of children, could suggest that combined measles, mumps and rubella vaccine could be given earlier (at 10-12 months of age), simultaneously with booster doses of diphtheria and tetanus toxoid and of trivalent oral poliovirus vaccine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8519358     DOI: 10.1007/BF00158792

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  19 in total

1.  Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure.

Authors:  P Albrecht; F A Ennis; E J Saltzman; S Krugman
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months.

Authors:  O Tidjani; B Grunitsky; N Guérin; D Lévy-Bruhl; N Lecam; C Xuereff; K Tatagan
Journal:  Lancet       Date:  1989-12-09       Impact factor: 79.321

3.  Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months.

Authors:  H C Whittle; G Mann; M Eccles; K O'Neill; L Jupp; P Hanlon; L Hanlon; V Marsh
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

Review 4.  Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs. 15 months.

Authors:  J S Marks; G F Hayden; W A Orenstein
Journal:  Am J Epidemiol       Date:  1982-09       Impact factor: 4.897

5.  Edmonston-Zagreb strain of measles vaccine: epidemiologic evaluation in Yugoslavia.

Authors:  D M Ikić
Journal:  Rev Infect Dis       Date:  1983 May-Jun

6.  Effect of timing of measles vaccination on compliance with immunizations during the second year of life.

Authors:  J L Sherrod; R Kane; J D Cherry; J Fricker; K Maples
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

7.  Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.

Authors:  H C Whittle; M G Rowland; G F Mann; W H Lamb; R A Lewis
Journal:  Lancet       Date:  1984-10-13       Impact factor: 79.321

8.  [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].

Authors:  M Just; R Berger; R Glück; A Wegmann
Journal:  Schweiz Med Wochenschr       Date:  1985-11-30

9.  Benefits, risks and costs of immunization for measles, mumps and rubella.

Authors:  C C White; J P Koplan; W A Orenstein
Journal:  Am J Public Health       Date:  1985-07       Impact factor: 9.308

10.  Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children.

Authors:  F L Ruben; E A Smith; S O Foster; H L Casey; J M Pifer; R B Wallace; A I Atta; W L Jones; R B Arnold; B E Teller; Z Q Shaikh; B Lourie; D L Eddins; S M Doko; W H Foege
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

View more
  4 in total

Review 1.  [Mumps vaccines: virological basis].

Authors:  A Ströhle; D Germann
Journal:  Soz Praventivmed       Date:  1995

2.  Evaluation of potentially achievable vaccination coverage of the second dose of measles containing vaccine with simultaneous administration and risk factors for missed opportunities among children in Zhejiang province, east China.

Authors:  Yu Hu; Yaping Chen; Ying Wang; Hui Liang
Journal:  Hum Vaccin Immunother       Date:  2018-01-23       Impact factor: 3.452

3.  Use of a microquantity enzyme immunoassay in a large-scale study of measles, mumps and rubella immunity in Italy.

Authors:  F Condorelli; A Stivala; R Gallo; A Marino; C M Battaglini; A Messina; G Russo; A Castro; G Scalia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 5.103

4.  Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.

Authors:  Sara Carazo; Marie-Noëlle Billard; Amélie Boutin; Gaston De Serres
Journal:  BMC Infect Dis       Date:  2020-03-29       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.